目的 观察莲芪胶囊联合TP方案治疗晚期食管癌的临床疗效。方法 选取2016年3月—2021年1月河南科技大学第一附属医院肿瘤内科接收的120例晚期食管癌患者，所有患者采用信封抽签法分为对照组和治疗组，各60例。对照组第1天静脉滴注紫杉醇注射液，175 mg/m²加入500 mL生理盐水溶液中，3 h内完成；第2天静脉滴注顺铂注射液，75 mg/m²加入500 mL生理盐水溶液中，3 h内完成。治疗组在对照组的基础上口服莲芪胶囊，3粒/次，3次/d。3周为1个治疗周期，治疗4个周期。观察两组疗效，比较血清肿瘤标志物、T淋巴细胞亚群、EORTC生命质量测定量表（QLQ-C30）评分、卡氏（KPS）评分。结果 治疗后，治疗组的客观缓解率、疾病控制率均高于对照组（P<0.05）。治疗后，两组QLQ-C30、KPS评分升高（P<0.05），且治疗组QLQ-C30、KPS评分高于对照组（P<0.05）。治疗后，两组血清癌胚抗原（CEA）、鳞状细胞癌抗原（SCC-Ag）、细胞角蛋白19片段（CYFRA21-1）水平均显著下降（P<0.05），且治疗组血清CEA、SCC-Ag、CYFRA21-1水平低于对照组（P<0.05）。治疗后，两组CD3⁺、CD4⁺、CD4⁺/CD8⁺下降，CD8⁺升高（P<0.05），且治疗后治疗组CD3⁺、CD4⁺、CD4⁺/CD8⁺低于对照组，CD8⁺高于对照组（P<0.05）。结论 莲芪胶囊联合TP方案治疗晚期食管癌可促进生活质量改善，有效降低血清肿瘤标志物水平，调节免疫功能，具有较好的临床应用价值。

Objective To observe the clinical effect of Lianqi Capsules combined with TP chemotherapy scheme in treatment of advanced esophageal cancer. Methods Patients (120 cases) with advanced esophageal cancer in Department of Oncology of the First Affiliated Hospital of Henan University of Science and Technology from March 2016 to January 2021 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were iv administered with Paclitaxel Injection at the first day, 175 mg/m² added into normal saline 500 mL, completed infusion within 3 h; and patients in the control group were iv administered with Cis-platin Injection at the second day, 75 mg/m² added into normal saline 500 mL, completed infusion within 3 h. Patients in the treatment group were po administered with Lianqi Capsules on the basis of the control group, 3 grains/time, three times daily. Three weeks was one treatment cycle, and patients in two groups were treated for 4 treatment cycles. After treatment, the clinical efficacies were evaluated, and serum tumor markers, T lymphocyte subsets, QLQ-C30 scores, and KPS scores in two groups were compared. Results After treatment, the objective remission rate and disease control rate in the treatment group were higher than those in the control group (P < 0.05). After treatment, the QLQ-C30 scores and KPS scores in two groups were significantly increased (P < 0.05), and the QLQ-C30 scores and KPS scores in the treatment group were higher than those in the control group (P < 0.05). After treatment, the serum levels of CEA, SCC-Ag, and CYFRA21-1 in two groups were significantly decreased (P < 0.05), and the serum levels of CEA, SCC-Ag, and CYFRA21-1 in the treatment group were lower than those in the control group (P < 0.05). After treatment, the CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in two groups were decreased, but the CD8⁺ in two groups were increased (P < 0.05). After treatment, the CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in the treatment group were lower than those in the control group, but the CD8⁺ in the treatment group was higher than those in the control group (P < 0.05). Conclusion Lianqi Capsules combined with TP chemotherapy scheme in treatment of advanced esophageal cancer can promote the improvement of quality of life, effectively reduce the level of serum tumor markers, regulate immune function, which has a good clinical application value.

R979.1

河南省医学科技攻关计划联合共建项目（2018020297）